The TGA is investigating reports of intestinal obstruction in patients using semaglutide and may consider updating the product information to include a warning about ileus. 

The watchdog said it had received four reports of adverse gastrointestinal events linked with semaglutide (Ozempic) to date. 

These included two cases of intestinal obstruction and one case each of small intestinal obstruction and ileus paralytic. 

But the TGA stressed that the notifications did not necessarily mean a causal link with the medicine had been established.